Universität zu Köln

Shahrizaila, Nortina, Lehmann, Helmar C. and Kuwabara, Satoshi (2021). Guillain-Barre syndrome. Lancet, 397 (10280). S. 1214 - 1229. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X

Full text not available from this repository.

Abstract

Guillain-Barre syndrome is the most common cause of acute flaccid paralysis worldwide. Most patients present with an antecedent illness, most commonly upper respiratory tract infection, before the onset of progressive motor weakness. Several microorganisms have been associated with Guillain-Barre syndrome, most notably Campylobacter jejuni, Zika virus, and in 2020, the severe acute respiratory syndrome coronavirus 2. In C jejuni-related Guillain-Barre syndrome, there is good evidence to support an autoantibody-mediated immune process that is triggered by molecular mimicry between structural components of peripheral nerves and the microorganism. Making a diagnosis of so-called classical Guillain-Barre syndrome is straightforward; however, the existing diagnostic criteria have limitations and can result in some variants of the syndrome being missed. Most patients with Guillain-Barre syndrome do well with immunotherapy, but a substantial proportion are left with disability, and death can occur. Results from the International Guillain-Barre Syndrome Outcome Study suggest that geographical variations exist in Guillain-Barre syndrome, including insufficient access to immunotherapy in low-income countries. There is a need to provide improved access to treatment for all patients with Guillain-Barre syndrome, and to develop effective disease-modifying therapies that can limit the extent of nerve injury. Clinical trials are currently underway to investigate some of the potential therapeutic candidates, including complement inhibitors, which, together with emerging data from large international collaborative studies on the syndrome, will contribute substantially to understanding the many facets of this disease.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Shahrizaila, Nortina UNSPECIFIED UNSPECIFIED UNSPECIFIED Lehmann, Helmar C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuwabara, Satoshi UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-580398
DOI:	10.1016/S0140-6736(21)00517-1
Journal or Publication Title:	Lancet
Volume:	397
Number:	10280
Page Range:	S. 1214 - 1229
Date:	2021
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1474-547X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CAMPYLOBACTER-JEJUNI INFECTION; EXPERIMENTAL ALLERGIC NEURITIS; BRAIN-STEM ENCEPHALITIS; INTRAVENOUS IMMUNOGLOBULIN; GANGLIOSIDE COMPLEXES; ANTI-GD1A ANTIBODY; CLINICAL-FEATURES; SYNDROME SUBTYPES; FISHER SYNDROME; IGG ANTIBODIES Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/58039